Llewellyn, Alexis <br/><br/>
Daclatasvir for the Treatment of Chronic Hepatitis C: A Critique of the Clinical and Economic Evidence.  [electronic resource] 

 -  PharmacoEconomics  10 2016 
 - 981-92 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Review 
<br/><br/><label>ISSN: </label>1179-2027 
<br/><br/><label>Standard No.: </label>10.1007/s40273-016-0418-8  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antiviral Agents--administration & dosage<br/>Carbamates<br/>Cost-Benefit Analysis<br/>Drug Therapy, Combination<br/>Genotype<br/>Hepacivirus--genetics<br/>Hepatitis C, Chronic--drug therapy<br/>Humans<br/>Imidazoles--administration & dosage<br/>Pyrrolidines<br/>Quality-Adjusted Life Years<br/>Randomized Controlled Trials as Topic<br/>Valine--analogs & derivatives